https://trial.medpath.com/news/pharmaceutical-industry-updates-trials-stocks-and-acquisitions 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-industry-updates-trials-stocks-and-acquisitions 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-shows-improvement-in-family-centered-care-practices-in-nicus-following-educational-intervention 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-shows-improvement-in-family-centered-care-practices-in-nicus-following-educational-intervention 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/insights-into-clinical-trials-and-research-practices 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insights-into-clinical-trials-and-research-practices 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-seattle-genetics-advanced-breast-cancer-drug-tukysa 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-seattle-genetics-advanced-breast-cancer-drug-tukysa 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cascada-silver-launches-phase-ii-drilling-at-angie-project 2025-01-09T22:52:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cascada-silver-launches-phase-ii-drilling-at-angie-project 2025-01-09T22:52:48+00:00 hourly 0.9 https://trial.medpath.com/news/chordia-therapeutics-secures-orphan-drug-designation-for-rogocekib-in-the-u-s 2025-01-09T22:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chordia-therapeutics-secures-orphan-drug-designation-for-rogocekib-in-the-u-s 2025-01-09T22:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-with-multiple-myeloma-dosed-in-esobiotec-s-trial-for-in-vivo-car-t-eso-t01 2025-01-09T22:21:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-with-multiple-myeloma-dosed-in-esobiotec-s-trial-for-in-vivo-car-t-eso-t01 2025-01-09T22:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-bbo-8520-fast-track-designation-for-krasg12c-mutant-mnsclc 2025-01-09T21:50:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-bbo-8520-fast-track-designation-for-krasg12c-mutant-mnsclc 2025-01-09T21:50:47+00:00 hourly 0.9 https://trial.medpath.com/news/igm-biosciences-halts-development-of-top-drugs-and-announces-workforce-reduction 2025-01-09T21:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igm-biosciences-halts-development-of-top-drugs-and-announces-workforce-reduction 2025-01-09T21:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/aptose-announces-first-aml-patients-dosed-with-tuspetinib-triplet-frontline-therapy-in-tuscany-trial 2025-01-09T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptose-announces-first-aml-patients-dosed-with-tuspetinib-triplet-frontline-therapy-in-tuscany-trial 2025-01-09T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/igm-biosciences-downgraded-by-bmo-capital-following-strategic-update 2025-01-09T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igm-biosciences-downgraded-by-bmo-capital-following-strategic-update 2025-01-09T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/intellia-therapeutics-announces-strategic-reorganization-and-2025-milestones 2025-01-09T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intellia-therapeutics-announces-strategic-reorganization-and-2025-milestones 2025-01-09T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-sa-advances-in-phase-3-trials-for-ulcerative-colitis-treatment 2025-01-09T20:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-sa-advances-in-phase-3-trials-for-ulcerative-colitis-treatment 2025-01-09T20:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/cage-bio-announces-phase-2b-trial-for-cgb-500-in-atopic-dermatitis-treatment 2025-01-09T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cage-bio-announces-phase-2b-trial-for-cgb-500-in-atopic-dermatitis-treatment 2025-01-09T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-discontinuations-of-ocrelizumab-in-ms-comparable-to-pivotal-trials 2025-01-09T19:25:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-discontinuations-of-ocrelizumab-in-ms-comparable-to-pivotal-trials 2025-01-09T19:25:25+00:00 hourly 0.9 https://trial.medpath.com/news/astra-merck-drugs-set-to-shake-up-liver-cancer-treatment 2025-01-09T18:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astra-merck-drugs-set-to-shake-up-liver-cancer-treatment 2025-01-09T18:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-concludes-enrolment-in-phase-ii-multiple-sclerosis-therapy-trial 2025-01-09T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contineum-concludes-enrolment-in-phase-ii-multiple-sclerosis-therapy-trial 2025-01-09T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/arovella-secures-20m-for-phase-1-clinical-trial-and-pipeline-expansion 2025-01-09T16:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arovella-secures-20m-for-phase-1-clinical-trial-and-pipeline-expansion 2025-01-09T16:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-car-t-clinical-trials-underway-at-roswell-park-for-solid-tumor-non-cancerous-diseases 2025-01-09T16:42:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-car-t-clinical-trials-underway-at-roswell-park-for-solid-tumor-non-cancerous-diseases 2025-01-09T16:42:51+00:00 hourly 0.9 https://trial.medpath.com/news/new-phase-2a-findings-on-img-007-treatment-for-atopic-dermatitis-show-promising-results 2025-01-09T16:40:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-phase-2a-findings-on-img-007-treatment-for-atopic-dermatitis-show-promising-results 2025-01-09T16:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ia-study-of-novel-anti-her2-antibody-drug-conjugate-gq1001-shows-promise-in-treating-her2-positive-advanced-solid-tumors 2025-01-09T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ia-study-of-novel-anti-her2-antibody-drug-conjugate-gq1001-shows-promise-in-treating-her2-positive-advanced-solid-tumors 2025-01-09T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-achieves-key-milestone-in-phase-3-abtect-trial-enrollment 2025-01-09T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-achieves-key-milestone-in-phase-3-abtect-trial-enrollment 2025-01-09T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-care-after-donor-stem-cell-transplant-can-be-safely-shared-between-transplant-centers-and-local-oncologists 2025-01-09T16:36:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-care-after-donor-stem-cell-transplant-can-be-safely-shared-between-transplant-centers-and-local-oncologists 2025-01-09T16:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-upgraded-to-overweight-by-morgan-stanley 2025-01-09T16:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-upgraded-to-overweight-by-morgan-stanley 2025-01-09T16:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-approach-to-cancer-treatment-targeted-protein-degradation 2025-01-09T16:28:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-approach-to-cancer-treatment-targeted-protein-degradation 2025-01-09T16:28:36+00:00 hourly 0.9 https://trial.medpath.com/news/thetis-pharmaceuticals-secures-9m-funding-to-advance-novel-oral-ibd-treatment 2025-01-09T16:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thetis-pharmaceuticals-secures-9m-funding-to-advance-novel-oral-ibd-treatment 2025-01-09T16:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/stroke-trial-tests-innovative-device-to-combat-arm-weakness 2025-01-09T16:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stroke-trial-tests-innovative-device-to-combat-arm-weakness 2025-01-09T16:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/durvalumab-plus-vaccine-therapy-shows-promise-in-bcg-unresponsive-nmibc 2025-01-09T16:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/durvalumab-plus-vaccine-therapy-shows-promise-in-bcg-unresponsive-nmibc 2025-01-09T16:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/gildeuretinol-shows-promise-in-halting-stargardt-disease-progression 2025-01-09T16:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gildeuretinol-shows-promise-in-halting-stargardt-disease-progression 2025-01-09T16:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/non-histone-lactylation-emerges-as-key-regulator-in-cancer-progression-and-therapeutic-target 2025-01-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-histone-lactylation-emerges-as-key-regulator-in-cancer-progression-and-therapeutic-target 2025-01-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/three-pronged-treatment-improves-prognosis-for-inoperable-liver-cancer 2025-01-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-pronged-treatment-improves-prognosis-for-inoperable-liver-cancer 2025-01-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/tenpoint-therapeutics-announces-positive-topline-data-from-brio-ii-phase-3-trial 2025-01-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenpoint-therapeutics-announces-positive-topline-data-from-brio-ii-phase-3-trial 2025-01-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/9mw2821-toripalimab-granted-breakthrough-therapy-designation-in-china-for-muc 2025-01-09T15:50:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/9mw2821-toripalimab-granted-breakthrough-therapy-designation-in-china-for-muc 2025-01-09T15:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/study-on-enhanced-oral-hygiene-program-for-cleft-patients 2025-01-09T15:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-on-enhanced-oral-hygiene-program-for-cleft-patients 2025-01-09T15:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/cristcot-s-phase-iii-ulcerative-colitis-suppository-trial-meets-endpoints 2025-01-09T15:28:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cristcot-s-phase-iii-ulcerative-colitis-suppository-trial-meets-endpoints 2025-01-09T15:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/argon-medical-announces-first-patient-enrollment-in-clean-pe-study-for-pulmonary-embolism-treatment 2025-01-09T15:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argon-medical-announces-first-patient-enrollment-in-clean-pe-study-for-pulmonary-embolism-treatment 2025-01-09T15:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-assessed-acupuncture-for-severe-combat-related-ptsd 2025-01-09T15:16:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-assessed-acupuncture-for-severe-combat-related-ptsd 2025-01-09T15:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biosciences-announces-complete-clinical-response-in-otc-hope-study-with-ecur-506 2025-01-09T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-biosciences-announces-complete-clinical-response-in-otc-hope-study-with-ecur-506 2025-01-09T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/effects-of-ultrasound-guided-recruitment-manoeuvres-on-postoperative-pulmonary-complications-in-obese-patients 2025-01-09T14:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/effects-of-ultrasound-guided-recruitment-manoeuvres-on-postoperative-pulmonary-complications-in-obese-patients 2025-01-09T14:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/biofidelity-and-cellcarta-partner-to-deploy-aspyre-lung-in-global-clinical-trials 2025-01-09T14:13:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofidelity-and-cellcarta-partner-to-deploy-aspyre-lung-in-global-clinical-trials 2025-01-09T14:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-cabometyx-cancer-drug-review-advances-as-fda-drops-advisory-meeting-requirement 2025-01-09T14:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-cabometyx-cancer-drug-review-advances-as-fda-drops-advisory-meeting-requirement 2025-01-09T14:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/limited-benefits-of-ctdna-testing-in-colorectal-cancer-surveillance-study-finds 2025-01-09T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/limited-benefits-of-ctdna-testing-in-colorectal-cancer-surveillance-study-finds 2025-01-09T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-supports-efficacy-of-opdivo-plus-yervoy-in-mrcc-treatment 2025-01-09T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-supports-efficacy-of-opdivo-plus-yervoy-in-mrcc-treatment 2025-01-09T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abdera-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-09T13:39:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abdera-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-09T13:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/first-u-s-h5n1-bird-flu-death-reported-in-louisiana-amid-low-overall-risk 2025-01-09T13:36:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-u-s-h5n1-bird-flu-death-reported-in-louisiana-amid-low-overall-risk 2025-01-09T13:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/mineralys-therapeutics-advances-lorundrostat-to-phase-2-trials 2025-01-09T13:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mineralys-therapeutics-advances-lorundrostat-to-phase-2-trials 2025-01-09T13:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-announces-r289-granted-orphan-drug-designation-by-the-fda-for-mds 2025-01-09T13:13:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigel-announces-r289-granted-orphan-drug-designation-by-the-fda-for-mds 2025-01-09T13:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/nivolumab-combined-with-cisplatin-and-radiotherapy-shows-improved-disease-free-survival-in-locally-advanced-scchn 2025-01-09T13:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nivolumab-combined-with-cisplatin-and-radiotherapy-shows-improved-disease-free-survival-in-locally-advanced-scchn 2025-01-09T13:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-nipocalimab-receives-fda-priority-review-for-generalized-myasthenia-gravis-treatment 2025-01-09T13:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-nipocalimab-receives-fda-priority-review-for-generalized-myasthenia-gravis-treatment 2025-01-09T13:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/nimbus-therapeutics-advances-oncology-pipeline-with-ind-submission-for-ndi-219216 2025-01-09T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nimbus-therapeutics-advances-oncology-pipeline-with-ind-submission-for-ndi-219216 2025-01-09T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/affinia-therapeutics-announces-development-candidate-for-bag3-dcm-and-completion-of-pre-ind-meeting-with-the-fda 2025-01-09T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affinia-therapeutics-announces-development-candidate-for-bag3-dcm-and-completion-of-pre-ind-meeting-with-the-fda 2025-01-09T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/rapport-therapeutics-announces-new-phase-1-data-supporting-rap-219-s-potential-for-cns-disorders 2025-01-09T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapport-therapeutics-announces-new-phase-1-data-supporting-rap-219-s-potential-for-cns-disorders 2025-01-09T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/puretech-s-cancer-drug-lyt-200-secures-fda-fast-track-status-for-leukemia-treatment 2025-01-09T12:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puretech-s-cancer-drug-lyt-200-secures-fda-fast-track-status-for-leukemia-treatment 2025-01-09T12:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/zentalis-cancer-drug-azenosertib-receives-fda-fast-track-status-for-ovarian-cancer-treatment 2025-01-09T12:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zentalis-cancer-drug-azenosertib-receives-fda-fast-track-status-for-ovarian-cancer-treatment 2025-01-09T12:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/peerbridge-health-launches-cor-insight-trial-for-ai-enabled-cardiac-and-cardiopulmonary-diagnostics 2025-01-09T12:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peerbridge-health-launches-cor-insight-trial-for-ai-enabled-cardiac-and-cardiopulmonary-diagnostics 2025-01-09T12:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-based-verdiva-launches-with-410m-and-an-oral-glp-1ra-candidate 2025-01-09T11:54:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-based-verdiva-launches-with-410m-and-an-oral-glp-1ra-candidate 2025-01-09T11:54:49+00:00 hourly 0.9 https://trial.medpath.com/news/european-pharmaceutical-industry-pushes-for-rapid-digital-package-insert-transition 2025-01-09T11:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-pharmaceutical-industry-pushes-for-rapid-digital-package-insert-transition 2025-01-09T11:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-enhances-partnership-with-agc-biologics-for-advanced-cell-therapy-manufacturing 2025-01-09T11:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genenta-enhances-partnership-with-agc-biologics-for-advanced-cell-therapy-manufacturing 2025-01-09T11:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-share-price-rises-on-positive-clinical-trial-results 2025-01-09T11:15:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-share-price-rises-on-positive-clinical-trial-results 2025-01-09T11:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/aviceda-therapeutics-secures-207-5-million-series-c-financing-for-geographic-atrophy-treatment 2025-01-09T11:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aviceda-therapeutics-secures-207-5-million-series-c-financing-for-geographic-atrophy-treatment 2025-01-09T11:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/lung-cancer-test-oracle-predicts-survival-better-than-current-methods 2025-01-09T10:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-cancer-test-oracle-predicts-survival-better-than-current-methods 2025-01-09T10:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/jeito-capital-leads-67-5m-series-b-financing-for-cardiovascular-gene-therapy 2025-01-09T10:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jeito-capital-leads-67-5m-series-b-financing-for-cardiovascular-gene-therapy 2025-01-09T10:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/second-university-of-minnesota-study-shows-no-hydroxychloroquine-benefit-in-covid-19-fight 2025-01-09T10:45:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/second-university-of-minnesota-study-shows-no-hydroxychloroquine-benefit-in-covid-19-fight 2025-01-09T10:45:22+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-and-radiographic-evaluation-of-silver-diamine-fluoride-versus-mineral-trioxide-aggregate-in-indirect-pulp-capping 2025-01-09T10:24:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-and-radiographic-evaluation-of-silver-diamine-fluoride-versus-mineral-trioxide-aggregate-in-indirect-pulp-capping 2025-01-09T10:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/regional-chemotherapy-for-colorectal-liver-metastases-a-retrospective-study 2025-01-09T10:14:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regional-chemotherapy-for-colorectal-liver-metastases-a-retrospective-study 2025-01-09T10:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/jimmy-carter-s-melanoma-treatment-journey-revolutionizes-immunotherapy-acceptance-in-cancer-care 2025-01-09T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jimmy-carter-s-melanoma-treatment-journey-revolutionizes-immunotherapy-acceptance-in-cancer-care 2025-01-09T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-disease-market-set-to-surge-to-19-3b-by-2033-driven-by-novel-therapies 2025-01-09T09:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-disease-market-set-to-surge-to-19-3b-by-2033-driven-by-novel-therapies 2025-01-09T09:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/lyell-immunopharma-advances-next-generation-car-t-cell-therapy-impt-314-for-large-b-cell-lymphoma 2025-01-09T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lyell-immunopharma-advances-next-generation-car-t-cell-therapy-impt-314-for-large-b-cell-lymphoma 2025-01-09T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-announces-positive-topline-results 2025-01-09T08:57:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-announces-positive-topline-results 2025-01-09T08:57:18+00:00 hourly 0.9 https://trial.medpath.com/news/aardvark-therapeutics-strengthens-board-with-industry-leaders 2025-01-09T08:34:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aardvark-therapeutics-strengthens-board-with-industry-leaders 2025-01-09T08:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/diabetes-prevention-program-shows-long-term-success-in-delaying-type-2-diabetes 2025-01-09T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diabetes-prevention-program-shows-long-term-success-in-delaying-type-2-diabetes 2025-01-09T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-palforzia-r-for-toddlers-with-peanut-allergy 2025-01-09T08:10:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-approves-palforzia-r-for-toddlers-with-peanut-allergy 2025-01-09T08:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/biotest-submits-biologics-license-application-for-fibrinogen-to-the-fda 2025-01-09T08:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotest-submits-biologics-license-application-for-fibrinogen-to-the-fda 2025-01-09T08:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-study-links-vitiligo-to-elevated-cardiovascular-disease-risk 2025-01-09T08:00:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-study-links-vitiligo-to-elevated-cardiovascular-disease-risk 2025-01-09T08:00:06+00:00 hourly 0.9 https://trial.medpath.com/news/elinzanetant-meets-all-primary-and-secondary-endpoints-in-phase-iii-study-oasis-4 2025-01-09T07:53:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elinzanetant-meets-all-primary-and-secondary-endpoints-in-phase-iii-study-oasis-4 2025-01-09T07:53:11+00:00 hourly 0.9 https://trial.medpath.com/news/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-toiva-clinical-trial 2025-01-09T07:38:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-toiva-clinical-trial 2025-01-09T07:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/azafaros-to-present-at-j-p-morgan-s-43rd-annual-healthcare-conference 2025-01-09T07:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azafaros-to-present-at-j-p-morgan-s-43rd-annual-healthcare-conference 2025-01-09T07:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/evaluation-of-one-step-nucleic-acid-amplification-for-detection-of-lymph-node-metastases-in-endometrial-cancer 2025-01-09T07:36:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evaluation-of-one-step-nucleic-acid-amplification-for-detection-of-lymph-node-metastases-in-endometrial-cancer 2025-01-09T07:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-pharmaceuticals-announces-record-revenue-and-strong-financial-position-for-2024 2025-01-09T07:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmo-pharmaceuticals-announces-record-revenue-and-strong-financial-position-for-2024 2025-01-09T07:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-unique-psoriasis-care-perspectives-among-latine-patients-in-urban-healthcare-setting 2025-01-09T07:00:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-unique-psoriasis-care-perspectives-among-latine-patients-in-urban-healthcare-setting 2025-01-09T07:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/schizophrenia-market-forecasted-to-show-strong-growth-trajectory-by-2034 2025-01-09T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schizophrenia-market-forecasted-to-show-strong-growth-trajectory-by-2034 2025-01-09T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-celebrates-phase-3-win-in-prostate-cancer-with-viral-immunotherapy 2025-01-09T06:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candel-therapeutics-celebrates-phase-3-win-in-prostate-cancer-with-viral-immunotherapy 2025-01-09T06:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-liver-cancer-treatment-with-immunotherapy 2025-01-09T06:37:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-liver-cancer-treatment-with-immunotherapy 2025-01-09T06:37:43+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-to-announce-new-clinical-data-from-achieve-trial 2025-01-09T06:33:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-to-announce-new-clinical-data-from-achieve-trial 2025-01-09T06:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/life-sciences-industry-report-forecasts-glp-1s-ai-and-digital-health-to-drive-innovation-in-2025 2025-01-09T06:19:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-sciences-industry-report-forecasts-glp-1s-ai-and-digital-health-to-drive-innovation-in-2025 2025-01-09T06:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/ionic-liquids-enhance-skin-drug-delivery 2025-01-09T06:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionic-liquids-enhance-skin-drug-delivery 2025-01-09T06:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-pharmaceuticals-reports-progress-in-clinical-trials-and-strategic-growth-in-2024 2025-01-09T06:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmo-pharmaceuticals-reports-progress-in-clinical-trials-and-strategic-growth-in-2024 2025-01-09T06:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-sarclisa-subcutaneous-formulation-meets-co-primary-endpoints-in-iraklia-phase-3-study-for-multiple-myeloma 2025-01-09T06:03:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-sarclisa-subcutaneous-formulation-meets-co-primary-endpoints-in-iraklia-phase-3-study-for-multiple-myeloma 2025-01-09T06:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/geographic-and-financial-barriers-limit-access-to-revolutionary-cell-and-gene-therapies-mckesson-report-reveals 2025-01-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geographic-and-financial-barriers-limit-access-to-revolutionary-cell-and-gene-therapies-mckesson-report-reveals 2025-01-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gabapentin-doesn-t-increase-fall-risk-study-suggests 2025-01-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gabapentin-doesn-t-increase-fall-risk-study-suggests 2025-01-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/anacardio-raises-sek-205-million-and-reports-positive-phase-1b-data-of-ac01 2025-01-09T05:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anacardio-raises-sek-205-million-and-reports-positive-phase-1b-data-of-ac01 2025-01-09T05:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioanalysis-emerges-as-critical-foundation-for-precision-medicine-development 2025-01-09T05:42:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioanalysis-emerges-as-critical-foundation-for-precision-medicine-development 2025-01-09T05:42:43+00:00 hourly 0.9 https://trial.medpath.com/news/bitterroot-bio-announces-positive-phase-1-study-results-for-brb-002-in-healthy-volunteers 2025-01-09T05:37:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bitterroot-bio-announces-positive-phase-1-study-results-for-brb-002-in-healthy-volunteers 2025-01-09T05:37:59+00:00 hourly 0.9 https://trial.medpath.com/news/vivacelle-bio-to-showcase-phase-3-treatment-for-shock-and-trauma-at-bio-partnering-jpm-week-2025 2025-01-09T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivacelle-bio-to-showcase-phase-3-treatment-for-shock-and-trauma-at-bio-partnering-jpm-week-2025 2025-01-09T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-critical-gaps-in-uk-s-pharma-doctor-payment-disclosure-system 2025-01-09T05:15:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-critical-gaps-in-uk-s-pharma-doctor-payment-disclosure-system 2025-01-09T05:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/historical-medical-mistrust-and-safety-concerns-drive-covid-19-vaccine-hesitancy-among-black-women-study-reveals 2025-01-09T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/historical-medical-mistrust-and-safety-concerns-drive-covid-19-vaccine-hesitancy-among-black-women-study-reveals 2025-01-09T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amd-enters-ai-drug-discovery-space-with-20m-investment-in-absci 2025-01-09T02:29:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amd-enters-ai-drug-discovery-space-with-20m-investment-in-absci 2025-01-09T02:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-firms-expand-solo-global-phase-iii-activity-including-us-sites 2025-01-09T02:01:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-firms-expand-solo-global-phase-iii-activity-including-us-sites 2025-01-09T02:01:09+00:00 hourly 0.9 https://trial.medpath.com/news/racial-and-gender-microaggressions-during-pregnancy-linked-to-elevated-postpartum-blood-pressure 2025-01-09T02:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/racial-and-gender-microaggressions-during-pregnancy-linked-to-elevated-postpartum-blood-pressure 2025-01-09T02:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-astellas-pharma-s-revised-snda-for-izervay-in-geographic-atrophy-treatment 2025-01-09T01:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-astellas-pharma-s-revised-snda-for-izervay-in-geographic-atrophy-treatment 2025-01-09T01:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/seikagaku-s-pain-drug-may-need-more-tailored-indication-rems-for-approval 2025-01-09T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seikagaku-s-pain-drug-may-need-more-tailored-indication-rems-for-approval 2025-01-09T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-s-promising-tce-oncology-assets-earn-buy-rating-from-joseph-stringer 2025-01-09T00:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-s-promising-tce-oncology-assets-earn-buy-rating-from-joseph-stringer 2025-01-09T00:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/genascence-s-gene-therapy-shows-promising-safety-profile-in-phase-1b-osteoarthritis-trial 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genascence-s-gene-therapy-shows-promising-safety-profile-in-phase-1b-osteoarthritis-trial 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/bonerge-announces-the-new-108-person-clinical-trial-exploring-skin-and-organ-anti-aging-innovations 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bonerge-announces-the-new-108-person-clinical-trial-exploring-skin-and-organ-anti-aging-innovations 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/bms-partners-with-transgene-to-test-opdivo-tg4010-vaccine-combo-in-pd-l1-low-nsclc 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-partners-with-transgene-to-test-opdivo-tg4010-vaccine-combo-in-pd-l1-low-nsclc 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-vaccination-shows-strong-t-cell-response-in-multiple-myeloma-patients-on-lenalidomide-therapy 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-vaccination-shows-strong-t-cell-response-in-multiple-myeloma-patients-on-lenalidomide-therapy 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/almirall-and-lilly-s-lebrikizumab-shows-promise-for-long-term-atopic-dermatitis-management 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/almirall-and-lilly-s-lebrikizumab-shows-promise-for-long-term-atopic-dermatitis-management 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/rq-bio-s-kavigale-receives-positive-chmp-opinion-for-covid-19-prevention-in-immunocompromised-patients 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rq-bio-s-kavigale-receives-positive-chmp-opinion-for-covid-19-prevention-in-immunocompromised-patients 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-clinical-trials-at-university-of-minnesota-offer-new-hope-for-glioblastoma-patients 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-clinical-trials-at-university-of-minnesota-offer-new-hope-for-glioblastoma-patients 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/combining-pi3kg-inhibition-with-radiotherapy-enhances-tumor-control-in-pancreatic-cancer 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combining-pi3kg-inhibition-with-radiotherapy-enhances-tumor-control-in-pancreatic-cancer 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-tuberculosis-treatment-new-antibiotic-btz-043-shows-promising-results 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-tuberculosis-treatment-new-antibiotic-btz-043-shows-promising-results 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-sa-advances-in-gut-microbiome-driven-therapies-for-cancer-treatment 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-sa-advances-in-gut-microbiome-driven-therapies-for-cancer-treatment 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-or-concurrent-atezolizumab-with-chemoradiation-for-locally-advanced-cervical-cancer 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-or-concurrent-atezolizumab-with-chemoradiation-for-locally-advanced-cervical-cancer 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-highlights-anticipated-2025-milestones-and-2024-key-accomplishments 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovio-highlights-anticipated-2025-milestones-and-2024-key-accomplishments 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-to-present-latest-clinical-data-of-hlx10-and-hlx22-at-2025-asco-gi 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-to-present-latest-clinical-data-of-hlx10-and-hlx22-at-2025-asco-gi 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-announces-breakthroughs-in-multiple-myeloma-and-ms-treatments 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-announces-breakthroughs-in-multiple-myeloma-and-ms-treatments 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/europe-wide-study-aims-to-accelerate-depression-treatment-discovery 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/europe-wide-study-aims-to-accelerate-depression-treatment-discovery 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/trisalus-life-sciences-announces-publication-of-pre-clinical-data-on-improved-delivery-of-embospheres-to-liver-tumors 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trisalus-life-sciences-announces-publication-of-pre-clinical-data-on-improved-delivery-of-embospheres-to-liver-tumors 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/prospective-validation-of-oracle-in-lung-adenocarcinoma-prognosis 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prospective-validation-of-oracle-in-lung-adenocarcinoma-prognosis 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clearpoint-neuro-achieves-fda-de-novo-marketing-authorization-for-smartflow-cannula 2025-01-08T23:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearpoint-neuro-achieves-fda-de-novo-marketing-authorization-for-smartflow-cannula 2025-01-08T23:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/aerwave-completes-first-in-human-study-of-lung-denervation-technology 2025-01-08T23:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aerwave-completes-first-in-human-study-of-lung-denervation-technology 2025-01-08T23:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/jpmorgan-raises-vir-biotechnology-price-target-to-14 2025-01-08T22:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jpmorgan-raises-vir-biotechnology-price-target-to-14 2025-01-08T22:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/viking-therapeutics-initiates-phase-2-trial-for-oral-vk2735-in-obesity-treatment 2025-01-08T22:28:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viking-therapeutics-initiates-phase-2-trial-for-oral-vk2735-in-obesity-treatment 2025-01-08T22:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/cognition-therapeutics-ceo-to-present-at-upcoming-healthcare-conferences 2025-01-08T22:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognition-therapeutics-ceo-to-present-at-upcoming-healthcare-conferences 2025-01-08T22:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/updates-on-ruxolitinib-combinations-for-mpns-from-ash-2024 2025-01-08T22:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updates-on-ruxolitinib-combinations-for-mpns-from-ash-2024 2025-01-08T22:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-advances-sma-treatment-apitegromab-towards-commercialization 2025-01-08T21:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-advances-sma-treatment-apitegromab-towards-commercialization 2025-01-08T21:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-announces-strategic-priorities-and-outlook-for-2025-and-2026 2025-01-08T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zymeworks-announces-strategic-priorities-and-outlook-for-2025-and-2026 2025-01-08T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-health-pioneers-use-of-novel-pvad-system-in-cardiology 2025-01-08T21:01:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-health-pioneers-use-of-novel-pvad-system-in-cardiology 2025-01-08T21:01:05+00:00 hourly 0.9 https://trial.medpath.com/news/c-reactive-protein-identified-as-key-biomarker-for-hidradenitis-suppurativa-treatment-efficacy 2025-01-08T21:00:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c-reactive-protein-identified-as-key-biomarker-for-hidradenitis-suppurativa-treatment-efficacy 2025-01-08T21:00:43+00:00 hourly 0.9 https://trial.medpath.com/news/tiziana-life-sciences-advances-in-immunomodulation-therapies-and-clinical-trials 2025-01-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tiziana-life-sciences-advances-in-immunomodulation-therapies-and-clinical-trials 2025-01-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dx-vx-advances-ferritin-based-universal-coronavirus-vaccine-to-phase-2-trials-following-promising-phase-1-results 2025-01-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dx-vx-advances-ferritin-based-universal-coronavirus-vaccine-to-phase-2-trials-following-promising-phase-1-results 2025-01-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/physiomics-project-and-cambridge-cognition-make-strides-in-medical-research 2025-01-08T20:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physiomics-project-and-cambridge-cognition-make-strides-in-medical-research 2025-01-08T20:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/tech-innovations-and-strategic-partnerships-highlight-ces-2025 2025-01-08T20:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tech-innovations-and-strategic-partnerships-highlight-ces-2025 2025-01-08T20:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/testing-the-progress-of-precision-prostate-cancer-screening 2025-01-08T20:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/testing-the-progress-of-precision-prostate-cancer-screening 2025-01-08T20:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/cofactor-genomics-inc-announces-ceo-transition-and-highlights-clinical-trial-successes 2025-01-08T20:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cofactor-genomics-inc-announces-ceo-transition-and-highlights-clinical-trial-successes 2025-01-08T20:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-xenotransplantation-genetically-modified-porcine-heart-transplanted-into-human 2025-01-08T19:53:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-xenotransplantation-genetically-modified-porcine-heart-transplanted-into-human 2025-01-08T19:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-halts-varipulse-pulsed-field-ablation-cases-in-the-us 2025-01-08T19:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-halts-varipulse-pulsed-field-ablation-cases-in-the-us 2025-01-08T19:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/disitamab-vedotin-and-toripalimab-show-promising-results-in-urothelial-carcinoma-treatment 2025-01-08T19:18:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disitamab-vedotin-and-toripalimab-show-promising-results-in-urothelial-carcinoma-treatment 2025-01-08T19:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/unc-breakthrough-research-on-food-allergy-drug-featured-in-national-geographic 2025-01-08T19:17:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unc-breakthrough-research-on-food-allergy-drug-featured-in-national-geographic 2025-01-08T19:17:53+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-addresses-market-rumors-and-updates-on-ht-001-clinical-trial-progress 2025-01-08T18:50:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-addresses-market-rumors-and-updates-on-ht-001-clinical-trial-progress 2025-01-08T18:50:47+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-announces-positive-topline-results-from-ares-study 2025-01-08T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-announces-positive-topline-results-from-ares-study 2025-01-08T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/eirion-reports-positive-results-in-topical-hair-loss-therapy-trial 2025-01-08T18:01:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eirion-reports-positive-results-in-topical-hair-loss-therapy-trial 2025-01-08T18:01:46+00:00 hourly 0.9 https://trial.medpath.com/news/adcentrx-initiates-phase-1a-b-study-for-adrx-0405-targeting-steap1-in-advanced-solid-tumours 2025-01-08T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adcentrx-initiates-phase-1a-b-study-for-adrx-0405-targeting-steap1-in-advanced-solid-tumours 2025-01-08T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hoag-family-cancer-institute-advances-glioblastoma-treatment-with-innovative-clinical-trials 2025-01-08T17:40:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoag-family-cancer-institute-advances-glioblastoma-treatment-with-innovative-clinical-trials 2025-01-08T17:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-sustained-5-weight-loss-to-establish-efficacy-of-new-antiobesity-medications 2025-01-08T17:40:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-sustained-5-weight-loss-to-establish-efficacy-of-new-antiobesity-medications 2025-01-08T17:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/catalyst-pharmaceuticals-secures-patent-settlement-with-teva-extending-firdapse-market-exclusivity-until-2035 2025-01-08T17:35:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalyst-pharmaceuticals-secures-patent-settlement-with-teva-extending-firdapse-market-exclusivity-until-2035 2025-01-08T17:35:34+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-offers-hope-for-type-2-diabetes-patients-struggling-with-weight-loss 2025-01-08T17:35:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-offers-hope-for-type-2-diabetes-patients-struggling-with-weight-loss 2025-01-08T17:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/tenvie-raises-200m-for-brain-drug-r-d-sana-spikes-on-single-patient-s-results 2025-01-08T16:51:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenvie-raises-200m-for-brain-drug-r-d-sana-spikes-on-single-patient-s-results 2025-01-08T16:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-announces-acquisition-agreement-for-bolt-medical 2025-01-08T16:43:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-announces-acquisition-agreement-for-bolt-medical 2025-01-08T16:43:41+00:00 hourly 0.9 https://trial.medpath.com/news/curevo-vaccine-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-08T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curevo-vaccine-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-08T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-stock-soars-on-prostate-cancer-trial-data 2025-01-08T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-stock-soars-on-prostate-cancer-trial-data 2025-01-08T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/indaptus-therapeutics-highlights-2024-achievements-and-2025-outlook 2025-01-08T16:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indaptus-therapeutics-highlights-2024-achievements-and-2025-outlook 2025-01-08T16:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/suven-life-sciences-shares-surge-10-following-phase-1-clinical-trial-announcement 2025-01-08T15:42:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/suven-life-sciences-shares-surge-10-following-phase-1-clinical-trial-announcement 2025-01-08T15:42:05+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-s-stock-receives-buy-rating-after-promising-phase-1-diabetes-treatment-results 2025-01-08T15:41:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-s-stock-receives-buy-rating-after-promising-phase-1-diabetes-treatment-results 2025-01-08T15:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-inc-achieves-key-milestone-in-phase-3-study-of-ameluz-for-superficial-basal-cell-carcinoma-treatment 2025-01-08T15:34:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-inc-achieves-key-milestone-in-phase-3-study-of-ameluz-for-superficial-basal-cell-carcinoma-treatment 2025-01-08T15:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-s-breakthrough-in-type-1-diabetes-treatment 2025-01-08T15:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-s-breakthrough-in-type-1-diabetes-treatment 2025-01-08T15:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/geron-stock-rallies-more-than-60-in-a-year-here-s-why 2025-01-08T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geron-stock-rallies-more-than-60-in-a-year-here-s-why 2025-01-08T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-reports-positive-phase-i-trial-results-for-glp-1ra-in-treating-hypoglycaemia 2025-01-08T15:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mbx-biosciences-reports-positive-phase-i-trial-results-for-glp-1ra-in-treating-hypoglycaemia 2025-01-08T15:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/updates-on-clinical-trials-funding-and-shelved-projects-in-ophthalmology 2025-01-08T15:20:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updates-on-clinical-trials-funding-and-shelved-projects-in-ophthalmology 2025-01-08T15:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/moma-therapeutics-advances-in-precision-medicine-with-new-parp1-inhibitor-and-clinical-updates 2025-01-08T14:54:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moma-therapeutics-advances-in-precision-medicine-with-new-parp1-inhibitor-and-clinical-updates 2025-01-08T14:54:04+00:00 hourly 0.9 https://trial.medpath.com/news/5-questions-novo-nordisk-must-answer-to-drive-its-stock-higher 2025-01-08T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/5-questions-novo-nordisk-must-answer-to-drive-its-stock-higher 2025-01-08T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/autobahn-therapeutics-initiates-phase-2-trial-for-abx-002-in-bipolar-depression-treatment 2025-01-08T14:38:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autobahn-therapeutics-initiates-phase-2-trial-for-abx-002-in-bipolar-depression-treatment 2025-01-08T14:38:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-cnp-104-for-primary-biliary-cholangitis 2025-01-08T14:38:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-cnp-104-for-primary-biliary-cholangitis 2025-01-08T14:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-posdinemab-granted-fda-fast-track-designation-for-alzheimer-s-treatment 2025-01-08T14:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-posdinemab-granted-fda-fast-track-designation-for-alzheimer-s-treatment 2025-01-08T14:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/lb-pharmaceuticals-reveals-phase-2-schizophrenia-data 2025-01-08T14:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lb-pharmaceuticals-reveals-phase-2-schizophrenia-data 2025-01-08T14:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/anokion-announces-positive-symptom-data-from-its-phase-2-trial-evaluating-kan-101-for-celiac-disease 2025-01-08T14:30:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anokion-announces-positive-symptom-data-from-its-phase-2-trial-evaluating-kan-101-for-celiac-disease 2025-01-08T14:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/quanta-receives-fda-ind-clearance-for-qtx3544-and-advances-kras-inhibitor-pipeline 2025-01-08T14:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanta-receives-fda-ind-clearance-for-qtx3544-and-advances-kras-inhibitor-pipeline 2025-01-08T14:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/community-engagement-methods-in-fm-tips-trial-to-be-discussed-at-pct-grand-rounds 2025-01-08T14:25:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-engagement-methods-in-fm-tips-trial-to-be-discussed-at-pct-grand-rounds 2025-01-08T14:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/inpatient-treatment-of-suicidality-a-systematic-review-of-clinical-trials 2025-01-08T14:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inpatient-treatment-of-suicidality-a-systematic-review-of-clinical-trials 2025-01-08T14:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/sellas-advances-cancer-drug-trials-with-key-2025-milestones-in-sight 2025-01-08T14:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sellas-advances-cancer-drug-trials-with-key-2025-milestones-in-sight 2025-01-08T14:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/avidity-biosciences-accelerates-path-to-first-drug-approval-and-expands-leadership-for-2025 2025-01-08T14:04:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avidity-biosciences-accelerates-path-to-first-drug-approval-and-expands-leadership-for-2025 2025-01-08T14:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-to-decide-on-agios-request-for-expanded-approval-of-pyrukynd-in-thalassemia-by-september-7 2025-01-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-to-decide-on-agios-request-for-expanded-approval-of-pyrukynd-in-thalassemia-by-september-7 2025-01-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/taiho-oncology-to-present-real-world-data-on-colorectal-cancer-treatments-at-asco-gi-2025 2025-01-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiho-oncology-to-present-real-world-data-on-colorectal-cancer-treatments-at-asco-gi-2025 2025-01-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-s-calma-trial-triples-alzheimer-s-patient-recruitment-with-ai-powered-strategy 2025-01-08T13:55:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-s-calma-trial-triples-alzheimer-s-patient-recruitment-with-ai-powered-strategy 2025-01-08T13:55:48+00:00 hourly 0.9 https://trial.medpath.com/news/bexion-pharmaceuticals-to-present-bxq-350-study-findings-at-asco-gi-2025 2025-01-08T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bexion-pharmaceuticals-to-present-bxq-350-study-findings-at-asco-gi-2025 2025-01-08T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/foresight-diagnostics-sets-strategic-goals-for-2025-following-a-year-of-significant-achievements 2025-01-08T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresight-diagnostics-sets-strategic-goals-for-2025-following-a-year-of-significant-achievements 2025-01-08T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-updates-in-second-line-therapies-for-lr-mds 2025-01-08T13:40:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-updates-in-second-line-therapies-for-lr-mds 2025-01-08T13:40:10+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-and-fresenius-kabi-canada-receive-health-canada-s-approval-for-fyb202-otulfi 2025-01-08T13:34:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-and-fresenius-kabi-canada-receive-health-canada-s-approval-for-fyb202-otulfi 2025-01-08T13:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-reports-encouraging-phase-1-data-for-two-cancer-drug-candidates 2025-01-08T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-reports-encouraging-phase-1-data-for-two-cancer-drug-candidates 2025-01-08T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-advances-oncology-pipeline-with-new-drug-candidates-and-clinical-trials 2025-01-08T13:24:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-therapeutics-advances-oncology-pipeline-with-new-drug-candidates-and-clinical-trials 2025-01-08T13:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/vigeneron-receives-fda-rare-pediatric-disease-designation-for-vg901-and-advances-in-phase-1b-retinitis-pigmentosa-trial 2025-01-08T13:24:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vigeneron-receives-fda-rare-pediatric-disease-designation-for-vg901-and-advances-in-phase-1b-retinitis-pigmentosa-trial 2025-01-08T13:24:12+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-highlights-2024-achievements-and-future-plans-in-annual-shareholder-letter 2025-01-08T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-highlights-2024-achievements-and-future-plans-in-annual-shareholder-letter 2025-01-08T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/replimune-advances-rp2-development-program-with-clinical-trials-for-melanoma-and-liver-cancer 2025-01-08T13:12:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/replimune-advances-rp2-development-program-with-clinical-trials-for-melanoma-and-liver-cancer 2025-01-08T13:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-and-challenges-in-cancer-care-and-treatment-planning 2025-01-08T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-and-challenges-in-cancer-care-and-treatment-planning 2025-01-08T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/denali-therapeutics-receives-fda-breakthrough-therapy-designation-for-tividenofusp-alfa-in-hunter-syndrome-treatment 2025-01-08T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denali-therapeutics-receives-fda-breakthrough-therapy-designation-for-tividenofusp-alfa-in-hunter-syndrome-treatment 2025-01-08T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/viva-biotech-s-portfolio-companies-showcase-significant-r-d-progress 2025-01-08T13:01:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viva-biotech-s-portfolio-companies-showcase-significant-r-d-progress 2025-01-08T13:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/tinivo-2-trial-highlights-challenges-in-ici-retreatment-for-advanced-rcc 2025-01-08T13:00:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tinivo-2-trial-highlights-challenges-in-ici-retreatment-for-advanced-rcc 2025-01-08T13:00:32+00:00 hourly 0.9 https://trial.medpath.com/news/denali-therapeutics-spinout-secures-200m-in-funding 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denali-therapeutics-spinout-secures-200m-in-funding 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/asher-bio-and-amgen-collaborate-on-clinical-trial-for-es-sclc-treatment 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asher-bio-and-amgen-collaborate-on-clinical-trial-for-es-sclc-treatment 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ocular-therapeutix-to-present-corporate-update-at-43rd-annual-j-p-morgan-healthcare-conference 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocular-therapeutix-to-present-corporate-update-at-43rd-annual-j-p-morgan-healthcare-conference 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sensei-biotherapeutics-announces-key-milestones-and-updates-for-solnerstotug-sns-101 2025-01-08T12:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensei-biotherapeutics-announces-key-milestones-and-updates-for-solnerstotug-sns-101 2025-01-08T12:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-life-sciences-reaches-critical-milestone-in-orca-ol-clinical-trial-for-cytisinicline 2025-01-08T12:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/achieve-life-sciences-reaches-critical-milestone-in-orca-ol-clinical-trial-for-cytisinicline 2025-01-08T12:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/edap-announces-first-pancreatic-cancer-patient-treated-with-proprietary-hifu-technology 2025-01-08T12:37:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edap-announces-first-pancreatic-cancer-patient-treated-with-proprietary-hifu-technology 2025-01-08T12:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-receives-ethics-approval-for-phase-ii-trial-of-lsalt-peptide-targeting-cs-aki 2025-01-08T12:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arch-biopartners-receives-ethics-approval-for-phase-ii-trial-of-lsalt-peptide-targeting-cs-aki 2025-01-08T12:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/biodesix-s-nodify-cdt-blood-test-shows-promise-in-lung-cancer-detection-study 2025-01-08T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biodesix-s-nodify-cdt-blood-test-shows-promise-in-lung-cancer-detection-study 2025-01-08T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-s-invikafusp-alfa-receives-fda-fast-track-designation-for-advanced-colorectal-cancer-treatment 2025-01-08T12:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marengo-s-invikafusp-alfa-receives-fda-fast-track-designation-for-advanced-colorectal-cancer-treatment 2025-01-08T12:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/compugen-advances-com503-into-phase-1-clinical-trial-for-advanced-solid-tumors 2025-01-08T12:27:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compugen-advances-com503-into-phase-1-clinical-trial-for-advanced-solid-tumors 2025-01-08T12:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/kamada-projects-continued-growth-with-2025-financial-guidance-and-strategic-expansions 2025-01-08T12:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kamada-projects-continued-growth-with-2025-financial-guidance-and-strategic-expansions 2025-01-08T12:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/stoke-therapeutics-receives-buy-rating-based-on-strong-phase-3-trial-design-and-early-results 2025-01-08T12:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stoke-therapeutics-receives-buy-rating-based-on-strong-phase-3-trial-design-and-early-results 2025-01-08T12:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/equivalence-confirmed-ct-p41-paves-the-way-for-affordable-osteoporosis-care 2025-01-08T12:12:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/equivalence-confirmed-ct-p41-paves-the-way-for-affordable-osteoporosis-care 2025-01-08T12:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/biostem-technologies-launches-clinical-trial-to-demonstrate-therapeutic-benefits-of-bioretain-technology-in-treating-diabetic-foot-ulcers 2025-01-08T12:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostem-technologies-launches-clinical-trial-to-demonstrate-therapeutic-benefits-of-bioretain-technology-in-treating-diabetic-foot-ulcers 2025-01-08T12:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-initiates-three-new-clinical-trials-for-sonelokimab-in-dermatology-and-rheumatology 2025-01-08T12:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonlake-initiates-three-new-clinical-trials-for-sonelokimab-in-dermatology-and-rheumatology 2025-01-08T12:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-clinical-alert-system-shows-10x-improvement-in-suicide-risk-screening-rates 2025-01-08T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-clinical-alert-system-shows-10x-improvement-in-suicide-risk-screening-rates 2025-01-08T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/lb-pharmaceuticals-announces-positive-topline-results-for-lb-102-in-schizophrenia-treatment 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lb-pharmaceuticals-announces-positive-topline-results-for-lb-102-in-schizophrenia-treatment 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-injectable-antipsychotics-show-promise-in-adolescent-bipolar-mania-management 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-acting-injectable-antipsychotics-show-promise-in-adolescent-bipolar-mania-management 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-s-revolutionary-breakthrough-in-type-1-diabetes-treatment 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-s-revolutionary-breakthrough-in-type-1-diabetes-treatment 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/renovorx-advances-targeted-cancer-therapy-with-tamp-platform 2025-01-08T11:29:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovorx-advances-targeted-cancer-therapy-with-tamp-platform 2025-01-08T11:29:36+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-immunotherapeutics-affirmed-with-buy-rating-for-strategic-clinical-expansion 2025-01-08T11:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonlake-immunotherapeutics-affirmed-with-buy-rating-for-strategic-clinical-expansion 2025-01-08T11:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/nephrology-month-in-review-december-2024 2025-01-08T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nephrology-month-in-review-december-2024 2025-01-08T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nextgen-class-of-2025-and-m-a-uptick-predicted 2025-01-08T10:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextgen-class-of-2025-and-m-a-uptick-predicted 2025-01-08T10:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-drug-discovery-foundation-invests-record-10m-in-alamar-biosciences-for-blood-based-diagnostic-platform 2025-01-08T10:47:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-drug-discovery-foundation-invests-record-10m-in-alamar-biosciences-for-blood-based-diagnostic-platform 2025-01-08T10:47:11+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-s-up421-therapy-shows-promising-results-in-type-1-diabetes 2025-01-08T10:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-s-up421-therapy-shows-promising-results-in-type-1-diabetes 2025-01-08T10:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/zhengye-biotechnology-raises-6-9-million-in-ipo-to-expand-veterinary-vaccine-portfolio 2025-01-08T10:41:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zhengye-biotechnology-raises-6-9-million-in-ipo-to-expand-veterinary-vaccine-portfolio 2025-01-08T10:41:08+00:00 hourly 0.9 https://trial.medpath.com/news/iros-and-halia-therapeutics-launch-pioneering-obesity-clinical-trial-in-uae 2025-01-08T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iros-and-halia-therapeutics-launch-pioneering-obesity-clinical-trial-in-uae 2025-01-08T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/positive-fda-feedback-for-phase-ii-trial-of-tiprelestat-in-pulmonary-arterial-hypertension 2025-01-08T09:41:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/positive-fda-feedback-for-phase-ii-trial-of-tiprelestat-in-pulmonary-arterial-hypertension 2025-01-08T09:41:32+00:00 hourly 0.9 https://trial.medpath.com/news/micron-biomedical-advances-needle-free-vaccine-technology-with-43-million-in-funding 2025-01-08T09:37:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/micron-biomedical-advances-needle-free-vaccine-technology-with-43-million-in-funding 2025-01-08T09:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/comparative-study-on-cefoxitin-administration-methods-for-preventing-surgical-site-infections 2025-01-08T09:35:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comparative-study-on-cefoxitin-administration-methods-for-preventing-surgical-site-infections 2025-01-08T09:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/alyssum-therapeutics-expands-series-a-funding-with-femhealth-ventures-participation 2025-01-08T09:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alyssum-therapeutics-expands-series-a-funding-with-femhealth-ventures-participation 2025-01-08T09:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/senate-investigation-reveals-concerning-impact-of-private-equity-ownership-on-healthcare-quality-and-safety 2025-01-08T09:14:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-investigation-reveals-concerning-impact-of-private-equity-ownership-on-healthcare-quality-and-safety 2025-01-08T09:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/experienced-industry-leader-dr-joerg-moeller-appointed-as-chief-executive-officer-of-antag-therapeutics 2025-01-08T09:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experienced-industry-leader-dr-joerg-moeller-appointed-as-chief-executive-officer-of-antag-therapeutics 2025-01-08T09:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/physiomics-plc-announces-approval-for-predict-onc-clinical-trial 2025-01-08T09:02:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physiomics-plc-announces-approval-for-predict-onc-clinical-trial 2025-01-08T09:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-s-novel-blood-test-shows-95-accuracy-in-early-cancer-detection-across-six-cancer-types 2025-01-08T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-s-novel-blood-test-shows-95-accuracy-in-early-cancer-detection-across-six-cancer-types 2025-01-08T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-prostate-cancer-imaging-technique-shows-promising-results-in-clinical-trials 2025-01-08T08:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-prostate-cancer-imaging-technique-shows-promising-results-in-clinical-trials 2025-01-08T08:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/aca-enrollment-hits-historic-23-6-million-as-enhanced-subsidies-face-2025-expiration 2025-01-08T08:24:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aca-enrollment-hits-historic-23-6-million-as-enhanced-subsidies-face-2025-expiration 2025-01-08T08:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/global-workplace-wellness-market-sees-substantial-growth 2025-01-08T08:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-workplace-wellness-market-sees-substantial-growth 2025-01-08T08:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-s-rybrevant-lazcluze-combination-shows-superior-survival-benefits-in-egfr-lung-cancer 2025-01-08T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-s-rybrevant-lazcluze-combination-shows-superior-survival-benefits-in-egfr-lung-cancer 2025-01-08T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-approves-padcev-in-combination-with-keytruda-for-advanced-urothelial-cancer 2025-01-08T07:30:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-nmpa-approves-padcev-in-combination-with-keytruda-for-advanced-urothelial-cancer 2025-01-08T07:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/aer-therapeutics-doses-first-patient-in-phase-2-clinical-trial-for-copd-treatment 2025-01-08T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aer-therapeutics-doses-first-patient-in-phase-2-clinical-trial-for-copd-treatment 2025-01-08T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-cognition-s-cantab-plays-key-role-in-schizophrenia-drug-approval 2025-01-08T07:28:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-cognition-s-cantab-plays-key-role-in-schizophrenia-drug-approval 2025-01-08T07:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-announces-promising-data-for-bi-1910-as-single-agent-from-phase-1-study-in-solid-tumors 2025-01-08T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-announces-promising-data-for-bi-1910-as-single-agent-from-phase-1-study-in-solid-tumors 2025-01-08T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/proteomic-analysis-reveals-new-insights-into-semaglutide-s-mechanism-of-action 2025-01-08T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteomic-analysis-reveals-new-insights-into-semaglutide-s-mechanism-of-action 2025-01-08T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/allurion-s-audacity-trial-achieves-one-co-primary-endpoint-misses-another 2025-01-08T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allurion-s-audacity-trial-achieves-one-co-primary-endpoint-misses-another 2025-01-08T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/25-of-patients-recruited-in-guard-therapeutics-phase-2b-pointer-study 2025-01-08T07:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/25-of-patients-recruited-in-guard-therapeutics-phase-2b-pointer-study 2025-01-08T07:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-projects-mixed-trends-in-childhood-atopic-dermatitis-through-2050 2025-01-08T07:00:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-study-projects-mixed-trends-in-childhood-atopic-dermatitis-through-2050 2025-01-08T07:00:52+00:00 hourly 0.9 https://trial.medpath.com/news/azafaros-receives-orphan-drug-designations-for-nizubaglustat-in-gm1-gangliosidosis-treatment 2025-01-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azafaros-receives-orphan-drug-designations-for-nizubaglustat-in-gm1-gangliosidosis-treatment 2025-01-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-reports-promising-early-results-from-triple-combination-therapy-for-non-hodgkin-s-lymphoma 2025-01-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-reports-promising-early-results-from-triple-combination-therapy-for-non-hodgkin-s-lymphoma 2025-01-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ryght-ai-partners-with-qps-holdings-to-transform-clinical-trial-operations-using-ai-technology 2025-01-08T06:28:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryght-ai-partners-with-qps-holdings-to-transform-clinical-trial-operations-using-ai-technology 2025-01-08T06:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/in-home-rehabilitation-shows-promise-despite-healthcare-system-barriers 2025-01-08T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in-home-rehabilitation-shows-promise-despite-healthcare-system-barriers 2025-01-08T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/yale-surgeon-scientist-secures-fda-orphan-drug-designation-for-pembrolizumab-in-rare-respiratory-disease 2025-01-08T05:45:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-surgeon-scientist-secures-fda-orphan-drug-designation-for-pembrolizumab-in-rare-respiratory-disease 2025-01-08T05:45:12+00:00 hourly 0.9 https://trial.medpath.com/news/hormone-replacement-therapy-and-cancer-survival-a-longitudinal-cohort-study 2025-01-08T05:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hormone-replacement-therapy-and-cancer-survival-a-longitudinal-cohort-study 2025-01-08T05:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-says-its-hpv-vaccine-for-men-was-approved 2025-01-08T05:03:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-says-its-hpv-vaccine-for-men-was-approved 2025-01-08T05:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/corbus-pharmaceuticals-to-present-crb-701-clinical-data-at-asco-gu-2025 2025-01-08T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corbus-pharmaceuticals-to-present-crb-701-clinical-data-at-asco-gu-2025 2025-01-08T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mifepristone-as-weekly-contraceptive-performs-beyond-expectations-in-b-clinical-trials-b 2025-01-08T04:18:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mifepristone-as-weekly-contraceptive-performs-beyond-expectations-in-b-clinical-trials-b 2025-01-08T04:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-q3-2024-earnings-highlight-clinical-progress-in-gene-therapy 2025-01-08T03:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocugen-q3-2024-earnings-highlight-clinical-progress-in-gene-therapy 2025-01-08T03:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-announces-strategic-split-and-restructured-gilead-partnership-in-major-corporate-overhaul 2025-01-08T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-announces-strategic-split-and-restructured-gilead-partnership-in-major-corporate-overhaul 2025-01-08T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/nicklaus-childrens-hospital-advances-pediatric-cancer-treatment-with-targeted-therapy 2025-01-08T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nicklaus-childrens-hospital-advances-pediatric-cancer-treatment-with-targeted-therapy 2025-01-08T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-cfo-kenneth-myszkowski-sells-893095-in-stock 2025-01-08T02:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-cfo-kenneth-myszkowski-sells-893095-in-stock 2025-01-08T02:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-s-phase-iia-derma-data-in-cancer-b-patients-b-propels-its-stock-bioworld 2025-01-08T02:16:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-s-phase-iia-derma-data-in-cancer-b-patients-b-propels-its-stock-bioworld 2025-01-08T02:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-b-clinical-b-utility-of 2025-01-08T02:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-b-clinical-b-utility-of 2025-01-08T02:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/advancing-immunotherapy-for-glioblastoma-duke-research-blog 2025-01-08T00:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancing-immunotherapy-for-glioblastoma-duke-research-blog 2025-01-08T00:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/6-of-seniors-depressed-adhd-and-hormones-novel-antipsychotic-eases-schizophrenia 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/6-of-seniors-depressed-adhd-and-hormones-novel-antipsychotic-eases-schizophrenia 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/modified-consent-procedures-may-enhance-psychedelic-trials-validity 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modified-consent-procedures-may-enhance-psychedelic-trials-validity 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-phase-1-2-clinical-trial-for-rec-4539-in-small-cell-lung-cancer 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-phase-1-2-clinical-trial-for-rec-4539-in-small-cell-lung-cancer 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthroughs-and-partnerships-in-medical-technology-and-research 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthroughs-and-partnerships-in-medical-technology-and-research 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ferring-s-gut-microbiome-drug-shows-promise-in-phase-3-trial-for-c-diff 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ferring-s-gut-microbiome-drug-shows-promise-in-phase-3-trial-for-c-diff 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-immunitybio-s-bladder-cancer-drug-after-second-review 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-immunitybio-s-bladder-cancer-drug-after-second-review 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-and-inovio-to-aim-immunotherapy-at-hard-to-treat-brain-tumour 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-and-inovio-to-aim-immunotherapy-at-hard-to-treat-brain-tumour 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/synairgen-advances-to-phase-3-trial-of-inhaled-covid-19-treatment-sng001 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synairgen-advances-to-phase-3-trial-of-inhaled-covid-19-treatment-sng001 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-pharmaceutica-reports-progress-and-future-plans-for-its-r-d-portfolio 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basilea-pharmaceutica-reports-progress-and-future-plans-for-its-r-d-portfolio 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/modified-consent-procedures-may-enhance-psychedelic-drug-trials 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modified-consent-procedures-may-enhance-psychedelic-drug-trials 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/trametinib-shows-breakthrough-results-in-children-with-severe-genetic-heart-condition 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trametinib-shows-breakthrough-results-in-children-with-severe-genetic-heart-condition 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-4-month-tb-treatment-regimen-shows-effectiveness-comparable-to-standard-6-month-regimen 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-4-month-tb-treatment-regimen-shows-effectiveness-comparable-to-standard-6-month-regimen 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthroughs-in-non-small-cell-lung-cancer-research-highlight-new-treatment-pathways 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthroughs-in-non-small-cell-lung-cancer-research-highlight-new-treatment-pathways 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-decision-on-atara-biotherapeutics-tab-cel-expected-soon 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-decision-on-atara-biotherapeutics-tab-cel-expected-soon 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-roctavian-receives-conditional-approval-in-europe-for-haemophilia-a-treatment 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-s-roctavian-receives-conditional-approval-in-europe-for-haemophilia-a-treatment 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/comparative-evaluation-of-high-flow-nasal-cannula-hfnc-vs-conventional-oxygen-therapy-cot-in-infants-after-non-cardiac-surgery 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comparative-evaluation-of-high-flow-nasal-cannula-hfnc-vs-conventional-oxygen-therapy-cot-in-infants-after-non-cardiac-surgery 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/heart-device-impresses-fda-stryker-acquires-inari-medical 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heart-device-impresses-fda-stryker-acquires-inari-medical 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alebund-pharmaceuticals-completes-series-c-financing-of-rmb-550-million 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alebund-pharmaceuticals-completes-series-c-financing-of-rmb-550-million 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/centessa-pharmaceuticals-appoints-stephen-kanes-md-phd-as-chief-medical-officer 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centessa-pharmaceuticals-appoints-stephen-kanes-md-phd-as-chief-medical-officer 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-announces-promising-results-from-beacon-study-for-briquilimab-in-chronic-spontaneous-urticaria 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jasper-therapeutics-announces-promising-results-from-beacon-study-for-briquilimab-in-chronic-spontaneous-urticaria 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-announces-key-developments-and-achievements-in-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansa-biopharma-announces-key-developments-and-achievements-in-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-tracks-neurovive-s-traumatic-brain-injury-drug 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fast-tracks-neurovive-s-traumatic-brain-injury-drug 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/patient-reported-qol-outcomes-of-initial-cll-treatments-highlighted-at-ash-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-reported-qol-outcomes-of-initial-cll-treatments-highlighted-at-ash-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uab-clinical-trials-offer-opportunities-for-participation-in-groundbreaking-research 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uab-clinical-trials-offer-opportunities-for-participation-in-groundbreaking-research 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-expands-ophthalmology-pipeline-with-regenxbio-gene-therapy-deal 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-expands-ophthalmology-pipeline-with-regenxbio-gene-therapy-deal 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/celgenes-multiple-myeloma-orphan-drug-gets-fda-approval 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celgenes-multiple-myeloma-orphan-drug-gets-fda-approval 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-new-guidance-on-psychedelic-therapy-clinical-trials 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-new-guidance-on-psychedelic-therapy-clinical-trials 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/avadel-reports-significant-growth-in-lumryz-sales-and-patient-adoption-in-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avadel-reports-significant-growth-in-lumryz-sales-and-patient-adoption-in-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-reduced-surgical-complications-in-diabetic-patients 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-linked-to-reduced-surgical-complications-in-diabetic-patients 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/shorla-oncology-announces-u-s-food-and-drug-administration-fda 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shorla-oncology-announces-u-s-food-and-drug-administration-fda 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/class-action-lawsuit-filed-against-bioage-labs-inc-following-discontinuation-of-azelaprag-trial 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/class-action-lawsuit-filed-against-bioage-labs-inc-following-discontinuation-of-azelaprag-trial 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/targeting-cd30-in-diffuse-large-b-cell-lymphoma-where-does-it-fit-in 2025-01-07T23:59:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeting-cd30-in-diffuse-large-b-cell-lymphoma-where-does-it-fit-in 2025-01-07T23:59:22+00:00 hourly 0.9 https://trial.medpath.com/news/solid-biosciences-revolutionary-dual-route-gene-therapy-for-friedreich-s-ataxia-gains 2025-01-07T23:47:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solid-biosciences-revolutionary-dual-route-gene-therapy-for-friedreich-s-ataxia-gains 2025-01-07T23:47:58+00:00 hourly 0.9 https://trial.medpath.com/news/treating-brain-cancer-with-immunotherapy-stanford-medicine 2025-01-07T23:01:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treating-brain-cancer-with-immunotherapy-stanford-medicine 2025-01-07T23:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/b-precision-medicine-b-biotech-maze-therapeutics-files-for-a-100-million-ipo 2025-01-07T22:53:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-precision-medicine-b-biotech-maze-therapeutics-files-for-a-100-million-ipo 2025-01-07T22:53:02+00:00 hourly 0.9 https://trial.medpath.com/news/eoi-international-junior-gender-consultant-for-west-africa-ahgc 2025-01-07T21:39:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eoi-international-junior-gender-consultant-for-west-africa-ahgc 2025-01-07T21:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-new-guidance-on-sex-and-gender-considerations-in-medical-device-and-drug-development 2025-01-07T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-new-guidance-on-sex-and-gender-considerations-in-medical-device-and-drug-development 2025-01-07T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-therapeutics-swot-analysis-oncology-biotech-s-stock-faces-pivotal-year 2025-01-07T21:13:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-therapeutics-swot-analysis-oncology-biotech-s-stock-faces-pivotal-year 2025-01-07T21:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/a-single-center-single-arm-prospective-open-label-and-comparative-trial-to-evaluate-the-nature 2025-01-07T20:59:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-single-center-single-arm-prospective-open-label-and-comparative-trial-to-evaluate-the-nature 2025-01-07T20:59:56+00:00 hourly 0.9 https://trial.medpath.com/news/for-the-record-january-7-2025-dct-guidance-revised-short-form-policy-more 2025-01-07T20:58:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/for-the-record-january-7-2025-dct-guidance-revised-short-form-policy-more 2025-01-07T20:58:52+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-layoffs-increase-by-3-in-2024-fierce-biotech-reports 2025-01-07T20:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharma-layoffs-increase-by-3-in-2024-fierce-biotech-reports 2025-01-07T20:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/stereotactic-body-radiation-may-improve-survival-in-liver-cancer-subset 2025-01-07T20:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stereotactic-body-radiation-may-improve-survival-in-liver-cancer-subset 2025-01-07T20:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/who-to-develop-lenacapavir-and-hiv-testing-guidelines-managed-healthcare-executive 2025-01-07T20:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-to-develop-lenacapavir-and-hiv-testing-guidelines-managed-healthcare-executive 2025-01-07T20:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approvals-expand-initial-treatment-options-for-multiple-myeloma-national-cancer-institute 2025-01-07T18:50:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approvals-expand-initial-treatment-options-for-multiple-myeloma-national-cancer-institute 2025-01-07T18:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/prucalopride-tablets-for-chronic-idiopathic-constipation-b-launches-b-approved-for-180-day 2025-01-07T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prucalopride-tablets-for-chronic-idiopathic-constipation-b-launches-b-approved-for-180-day 2025-01-07T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-md-anderson-forms-5-year-strategic-alliance 2025-01-07T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-md-anderson-forms-5-year-strategic-alliance 2025-01-07T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/wegovy-and-zepbound-tipped-to-fuel-20b-boom-in-heart-failure-market-fierce-pharma 2025-01-07T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wegovy-and-zepbound-tipped-to-fuel-20b-boom-in-heart-failure-market-fierce-pharma 2025-01-07T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/francis-medical-secures-80m-series-c-funding-for-innovative-water-vapor-ablation-technology 2025-01-07T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/francis-medical-secures-80m-series-c-funding-for-innovative-water-vapor-ablation-technology 2025-01-07T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/dr-deangelo-on-the-b-fda-approval-b-of-blinatumomab-consolidation-in-cd19-ph-b-all 2025-01-07T15:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-deangelo-on-the-b-fda-approval-b-of-blinatumomab-consolidation-in-cd19-ph-b-all 2025-01-07T15:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/structure-therapeutics-earns-buy-rating-for-innovative-oral-obesity-treatments 2025-01-07T15:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structure-therapeutics-earns-buy-rating-for-innovative-oral-obesity-treatments 2025-01-07T15:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-advances-cns-gene-therapy-with-capsida-through-40-million-option 2025-01-07T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-advances-cns-gene-therapy-with-capsida-through-40-million-option 2025-01-07T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/jefferies-upgrades-instil-bio-highlighting-potential-of-syn2510-in-cancer-treatment 2025-01-07T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jefferies-upgrades-instil-bio-highlighting-potential-of-syn2510-in-cancer-treatment 2025-01-07T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/avenzo-therapeutics-and-dualitybio-announce-exclusive-global-license-for-potential-best-in-class-egfr-her3-antibody-drug-conjugate 2025-01-07T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avenzo-therapeutics-and-dualitybio-announce-exclusive-global-license-for-potential-best-in-class-egfr-her3-antibody-drug-conjugate 2025-01-07T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/short-course-radiation-therapy-shows-promise-for-older-glioblastoma-patients 2025-01-07T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/short-course-radiation-therapy-shows-promise-for-older-glioblastoma-patients 2025-01-07T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-greenlights-first-stem-cell-therapy-on-mixed-clinical-findings-citeline 2025-01-07T13:19:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-greenlights-first-stem-cell-therapy-on-mixed-clinical-findings-citeline 2025-01-07T13:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/sling-therapeutics-appoints-andrew-guggenhime-to-its-board-of-directors 2025-01-07T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sling-therapeutics-appoints-andrew-guggenhime-to-its-board-of-directors 2025-01-07T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/marvel-biosciences-secures-funding-for-phase-1-clinical-trials-of-mb-204 2025-01-07T12:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marvel-biosciences-secures-funding-for-phase-1-clinical-trials-of-mb-204 2025-01-07T12:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/analyst-recommends-buying-arcturus-therapeutics-shares-due-to-h5n1-vaccine-demand 2025-01-07T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analyst-recommends-buying-arcturus-therapeutics-shares-due-to-h5n1-vaccine-demand 2025-01-07T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/promising-phase-1-2-results-for-acelyrin-s-lonigutamab-support-buy-rating 2025-01-07T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-phase-1-2-results-for-acelyrin-s-lonigutamab-support-buy-rating 2025-01-07T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/xeltis-announces-completion-of-enrolment-in-eu-pivotal-trial-for-axess-and-prepares-for 2025-01-07T09:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xeltis-announces-completion-of-enrolment-in-eu-pivotal-trial-for-axess-and-prepares-for 2025-01-07T09:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/bial-announces-first-patient-out-in-its-phase-2-clinical-trial-of-bia-28-6156-biospace 2025-01-07T09:01:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bial-announces-first-patient-out-in-its-phase-2-clinical-trial-of-bia-28-6156-biospace 2025-01-07T09:01:28+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-studies-show-improved-survival-rates-in-pediatric-aml-transplantation 2025-01-07T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-studies-show-improved-survival-rates-in-pediatric-aml-transplantation 2025-01-07T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-and-value-based-cancer-care-navigating-implementation-challenges-in-academic-and-community-settings 2025-01-07T08:50:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-and-value-based-cancer-care-navigating-implementation-challenges-in-academic-and-community-settings 2025-01-07T08:50:38+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-announces-fda-clearance-for-new-back-pain-treatment 2025-01-07T08:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-announces-fda-clearance-for-new-back-pain-treatment 2025-01-07T08:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-publication-highlights-safety-and-potential-benefits-of-redosing-diamyd-r-precision 2025-01-07T08:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-publication-highlights-safety-and-potential-benefits-of-redosing-diamyd-r-precision 2025-01-07T08:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/qlife-provides-update-on-operational-progress-in-china-qlife-holding-ab-cision-news 2025-01-07T08:01:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qlife-provides-update-on-operational-progress-in-china-qlife-holding-ab-cision-news 2025-01-07T08:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/qnovia-inc-announces-first-patient-dosed-in-u-s-phase-1-study-for-respirxtm-nicotine-inhaler 2025-01-07T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qnovia-inc-announces-first-patient-dosed-in-u-s-phase-1-study-for-respirxtm-nicotine-inhaler 2025-01-07T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/drug-pricing-reform-shows-promise-as-2000-medicare-out-of-pocket-cap-set-for-2025 2025-01-07T07:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-pricing-reform-shows-promise-as-2000-medicare-out-of-pocket-cap-set-for-2025 2025-01-07T07:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/next-lifts-full-year-guidance-gsk-drug-gets-new-breakthrough-designation-sharecast-com 2025-01-07T07:36:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-lifts-full-year-guidance-gsk-drug-gets-new-breakthrough-designation-sharecast-com 2025-01-07T07:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/cormedix-inc-announces-preliminary-fourth-quarter-2024-results-and-provides-business-update 2025-01-07T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cormedix-inc-announces-preliminary-fourth-quarter-2024-results-and-provides-business-update 2025-01-07T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/opthea-reports-positive-phase-1b-dme-trial-results 2025-01-07T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opthea-reports-positive-phase-1b-dme-trial-results 2025-01-07T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/4sc-ag-4sc-announces-update-relating-to-resminostat-s-kinselby-marketing 2025-01-07T07:02:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4sc-ag-4sc-announces-update-relating-to-resminostat-s-kinselby-marketing 2025-01-07T07:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/evolution-of-managed-care-three-decades-of-healthcare-transformation-and-future-outlook 2025-01-07T07:00:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolution-of-managed-care-three-decades-of-healthcare-transformation-and-future-outlook 2025-01-07T07:00:20+00:00 hourly 0.9 https://trial.medpath.com/news/hope-therapeutics-to-acquire-kadima-neuropsychiatry-institute-as-flagship-for-global-interventional-psychiatry-network 2025-01-07T06:52:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-therapeutics-to-acquire-kadima-neuropsychiatry-institute-as-flagship-for-global-interventional-psychiatry-network 2025-01-07T06:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/global-dna-sequencing-market-set-to-reach-106-billion-by-2034-driven-by-next-generation-technologies 2025-01-07T06:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-dna-sequencing-market-set-to-reach-106-billion-by-2034-driven-by-next-generation-technologies 2025-01-07T06:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/interius-biotherapeutics-expands-phase-1-clinical-trial-of-int2104-into-europe 2025-01-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/interius-biotherapeutics-expands-phase-1-clinical-trial-of-int2104-into-europe 2025-01-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alivegen-receives-fda-orphan-drug-designation-for-alg-801-for-pulmonary-arterial-hypertension 2025-01-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alivegen-receives-fda-orphan-drug-designation-for-alg-801-for-pulmonary-arterial-hypertension 2025-01-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-s-anticancer-drug-candidate-emerges-as-us-partner-s-core-pipeline-kbr 2025-01-07T04:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abl-bio-s-anticancer-drug-candidate-emerges-as-us-partner-s-core-pipeline-kbr 2025-01-07T04:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-partners-with-orna-in-700m-deal-to-develop-in-vivo-gene-therapies-for-blood-disorders 2025-01-07T04:19:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-partners-with-orna-in-700m-deal-to-develop-in-vivo-gene-therapies-for-blood-disorders 2025-01-07T04:19:51+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-s-syh2059-tablets-gain-clinical-trial-approval-in-china 2025-01-07T03:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-pharmaceutical-s-syh2059-tablets-gain-clinical-trial-approval-in-china 2025-01-07T03:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/candid-therapeutics-and-wuxi-biologics-forge-925m-deal-for-novel-t-cell-engager-development 2025-01-07T03:36:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candid-therapeutics-and-wuxi-biologics-forge-925m-deal-for-novel-t-cell-engager-development 2025-01-07T03:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/msd-acquires-wuxi-biologics-irish-vaccine-facility-for-500m-amid-regulatory-pressures 2025-01-07T03:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msd-acquires-wuxi-biologics-irish-vaccine-facility-for-500m-amid-regulatory-pressures 2025-01-07T03:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/norgine-submits-marketing-authorisation-application-to-the-european-medicines-agency-for 2025-01-07T01:12:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norgine-submits-marketing-authorisation-application-to-the-european-medicines-agency-for 2025-01-07T01:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/cell-gene-therapies-pink-sheet-citeline 2025-01-07T01:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-gene-therapies-pink-sheet-citeline 2025-01-07T01:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/the-registrational-clinical-data-of-glecirasib-was-published-in-nature-medicine 2025-01-07T00:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-registrational-clinical-data-of-glecirasib-was-published-in-nature-medicine 2025-01-07T00:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-expands-gene-therapy-portfolio-with-decibel-therapeutics-acquisition 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-expands-gene-therapy-portfolio-with-decibel-therapeutics-acquisition 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verona-to-test-copd-hopeful-ensifentrine-in-covid-19-patients 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verona-to-test-copd-hopeful-ensifentrine-in-covid-19-patients 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-anti-aging-company-just-released-disappointing 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-s-anti-aging-company-just-released-disappointing 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-achieves-breakthrough-in-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-achieves-breakthrough-in-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/odronextamab-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/odronextamab-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rapt-therapeutics-announces-initiation-of-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapt-therapeutics-announces-initiation-of-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-shows-ambroxol-safe-but-ineffective-for-parkinson-s-disease-dementia-cognitive-symptoms 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-shows-ambroxol-safe-but-ineffective-for-parkinson-s-disease-dementia-cognitive-symptoms 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-app-could-revolutionise-ophthalmic-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-app-could-revolutionise-ophthalmic-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eu-approves-enhertu-for-her2-low-breast-cancer-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-approves-enhertu-for-her2-low-breast-cancer-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ai-that-detects-heart-failure-using-a-stethoscope 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ai-that-detects-heart-failure-using-a-stethoscope 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dimerix-has-entered-into-a-development-and-license-agreement-for-japan 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dimerix-has-entered-into-a-development-and-license-agreement-for-japan 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-files-duchenne-muscular-dystrophy-gene-therapy-with-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-files-duchenne-muscular-dystrophy-gene-therapy-with-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisers-reject-new-use-for-pacira-nerve-block 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisers-reject-new-use-for-pacira-nerve-block 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/homozygous-familial-hypercholesterolemia-treatment-market-to-surge-by-2034 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/homozygous-familial-hypercholesterolemia-treatment-market-to-surge-by-2034 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eqs-news-immunic-highlights-2024-accomplishments-and 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eqs-news-immunic-highlights-2024-accomplishments-and 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pmv-pharmaceuticals-inc-pmvp 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pmv-pharmaceuticals-inc-pmvp 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/january-7-2025-after-tough-year-moderna-ceo-confronts 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/january-7-2025-after-tough-year-moderna-ceo-confronts 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aldeyras-reproxalap-for-dry-eye-disease-accepted-by-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aldeyras-reproxalap-for-dry-eye-disease-accepted-by-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-win-sets-up-rare-disease-drug-filing-for-csl 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-win-sets-up-rare-disease-drug-filing-for-csl 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-and-astrazeneca-highlight-tezspire-s-potential-in-copd-treatment-despite-trial-outcome 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-and-astrazeneca-highlight-tezspire-s-potential-in-copd-treatment-despite-trial-outcome 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-haemophilia-b-gene-therapy-meets-phase-3-primary-endpoint 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-haemophilia-b-gene-therapy-meets-phase-3-primary-endpoint 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/news-for-the-cardiac-and-vascular-medtech-and-biotech 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/news-for-the-cardiac-and-vascular-medtech-and-biotech 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-fda-approves-aop-health-s-rapiblyktm-landiolol-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-fda-approves-aop-health-s-rapiblyktm-landiolol-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-emrosi-for-rosacea-in-adults-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-emrosi-for-rosacea-in-adults-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/brainchild-bio-inc-to-clinically-advance-bcb-276-an 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainchild-bio-inc-to-clinically-advance-bcb-276-an 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-new-heart-failure-use-for-az-s-farxiga 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-new-heart-failure-use-for-az-s-farxiga 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vergent-bioscience-receives-fda-fast-track-designation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vergent-bioscience-receives-fda-fast-track-designation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bofa-cuts-denali-therapeutics-stock-target-as-als-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bofa-cuts-denali-therapeutics-stock-target-as-als-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-inc-rxrx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-pharmaceuticals-inc-rxrx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mammaprint-assay-identifies-subgroup-benefiting-from-extended-letrozole-therapy-in-early-stage-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mammaprint-assay-identifies-subgroup-benefiting-from-extended-letrozole-therapy-in-early-stage-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/halda-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halda-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/onl-therapeutics-strengthens-leadership-with-appointment-of-penny-fleck-as-chief-development-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onl-therapeutics-strengthens-leadership-with-appointment-of-penny-fleck-as-chief-development-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurotech-fda-update-on-nt-501-mactel-treatment-obn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurotech-fda-update-on-nt-501-mactel-treatment-obn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regenxbio-expands-mps-i-gene-therapy-trial-after-initial-data-review 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenxbio-expands-mps-i-gene-therapy-trial-after-initial-data-review 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immuneering-reports-positive-phase-2a-data-for-imm-1-104 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneering-reports-positive-phase-2a-data-for-imm-1-104 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-ucb-s-psoriasis-therapy-bimekizumab 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-ucb-s-psoriasis-therapy-bimekizumab 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/az-s-antibody-first-to-be-cleared-by-fda-for-covid-prevention 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/az-s-antibody-first-to-be-cleared-by-fda-for-covid-prevention 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tesaro-s-niraparib-approved-in-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tesaro-s-niraparib-approved-in-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advances-in-nephrology-breakthroughs-in-kidney-transplantation-and-disease-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advances-in-nephrology-breakthroughs-in-kidney-transplantation-and-disease-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-appoints-stephen-collins-m-d-ph-d-as-chief-medical-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bright-minds-biosciences-appoints-stephen-collins-m-d-ph-d-as-chief-medical-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/could-crispr-cure-hiv-us-biotech-excision-raises-60m-to-find-out 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/could-crispr-cure-hiv-us-biotech-excision-raises-60m-to-find-out 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-fda-accepts-nda-filing-for-bi-s-nintedanib 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-fda-accepts-nda-filing-for-bi-s-nintedanib 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-looks-to-digitise-drug-trials-with-koneksa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-looks-to-digitise-drug-trials-with-koneksa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-wild-card-drug-scemblix-gets-fda-nod-for-leukaemia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-wild-card-drug-scemblix-gets-fda-nod-for-leukaemia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-nasdaq-itrm-stock-quotes-forecast-and-news-summary 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterum-therapeutics-nasdaq-itrm-stock-quotes-forecast-and-news-summary 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/som-s-ai-discovered-drug-shows-promise-in-huntington-s-disease 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/som-s-ai-discovered-drug-shows-promise-in-huntington-s-disease 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bayer-merck-co-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bayer-merck-co-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-bans-use-of-lilly-regeneron-covid-drugs-due-to-omicron 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-bans-use-of-lilly-regeneron-covid-drugs-due-to-omicron 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-points-to-weaknesses-in-fda-accelerated-approval-path 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-points-to-weaknesses-in-fda-accelerated-approval-path 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-hpv-vaccine-shows-promise-in-long-term-cervical-cancer-prevention-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-hpv-vaccine-shows-promise-in-long-term-cervical-cancer-prevention-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/how-effective-are-glp-1-meds-for-weight-loss-in-people-without-diabetes 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-effective-are-glp-1-meds-for-weight-loss-in-people-without-diabetes 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-co-ltd-advances-in-narcolepsy-and-alzheimer-s-disease-treatments 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-co-ltd-advances-in-narcolepsy-and-alzheimer-s-disease-treatments 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cassava-sciences-provides-a-business-update 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cassava-sciences-provides-a-business-update 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-xenotransplantation-genetically-engineered-pig-hearts-show-promise-for-human-transplantation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-xenotransplantation-genetically-engineered-pig-hearts-show-promise-for-human-transplantation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-cytokinetics-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-cytokinetics-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/metseras-touts-powerful-weight-loss-results-again 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metseras-touts-powerful-weight-loss-results-again 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-announces-strategic-partnership 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verismo-therapeutics-announces-strategic-partnership 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-november-review-date-for-j-j-s-multiple-myeloma-car-t-cilta-cel 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-sets-november-review-date-for-j-j-s-multiple-myeloma-car-t-cilta-cel 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-chalks-hidradenitis-suppurativa-as-fifth-indication-for-bimzelx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-chalks-hidradenitis-suppurativa-as-fifth-indication-for-bimzelx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nippon-shinyakus-dmd-drug-fails-confirmatory-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nippon-shinyakus-dmd-drug-fails-confirmatory-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/agios-up-as-fda-gives-thermo-fisher-glioma-test-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agios-up-as-fda-gives-thermo-fisher-glioma-test-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/second-time-lucky-at-fda-for-citius-lymphoma-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/second-time-lucky-at-fda-for-citius-lymphoma-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verona-pharma-reports-strong-ohtuvayretm-launch-and-provides-preliminary-fourth-quarter-and-full-year-2024-financial-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verona-pharma-reports-strong-ohtuvayretm-launch-and-provides-preliminary-fourth-quarter-and-full-year-2024-financial-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunogen-elahere-wins-accelerated-fda-approval-for-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunogen-elahere-wins-accelerated-fda-approval-for-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/brainchild-bio-inc-to-clinically-advance-bcb-276-an 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainchild-bio-inc-to-clinically-advance-bcb-276-an 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/egg-maturation-supported-by-stem-cells-results-in-first-live 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egg-maturation-supported-by-stem-cells-results-in-first-live 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-updates-on-avicursen-primate-toxicology-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/percheron-therapeutics-updates-on-avicursen-primate-toxicology-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-appoints-pharmaceutical-leader 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bright-minds-biosciences-appoints-pharmaceutical-leader 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rsv-vaccines-add-guillain-barre-warning-conexiant 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rsv-vaccines-add-guillain-barre-warning-conexiant 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vyloy-zolbetuximab-uses-dosage-side-effects-warnings-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyloy-zolbetuximab-uses-dosage-side-effects-warnings-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/govorestat-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/govorestat-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lin-bioscience-inc-lin-bioscience-receives-u-s-fda-fast-track-designation-for-lbs-007 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lin-bioscience-inc-lin-bioscience-receives-u-s-fda-fast-track-designation-for-lbs-007 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/geron-corporation-gern-stock-price-news-quote-history-yahoo-finance 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geron-corporation-gern-stock-price-news-quote-history-yahoo-finance 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/inside-esmo-2024-treatments-trials-and-top-hcps-on-social-media 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inside-esmo-2024-treatments-trials-and-top-hcps-on-social-media 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fire1-raises-120m-to-develop-its-heart-failure 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fire1-raises-120m-to-develop-its-heart-failure 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-looks-at-pulling-speedy-approvals-for-three-cancer-drugs 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-looks-at-pulling-speedy-approvals-for-three-cancer-drugs 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizers-rsv-shot-clears-fda-adcomm-now-its-gsks-turn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizers-rsv-shot-clears-fda-adcomm-now-its-gsks-turn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-gives-abbvie-s-c-met-lung-cancer-adc-a-breakthrough-tag 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-gives-abbvie-s-c-met-lung-cancer-adc-a-breakthrough-tag 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-tracks-gsks-chronic-hep-b-therapy-bepirovirsen 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fast-tracks-gsks-chronic-hep-b-therapy-bepirovirsen 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-emrosi-for-rosacea-in-adults-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-emrosi-for-rosacea-in-adults-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-covid-19-mrna-vaccines-aim-to-revolutionise-cancer-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-covid-19-mrna-vaccines-aim-to-revolutionise-cancer-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-medtech-temporarily-pauses-u-s-varipulse-cases 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-medtech-temporarily-pauses-u-s-varipulse-cases 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/camurus-provides-regulatory-update-on-the-us-nda-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camurus-provides-regulatory-update-on-the-us-nda-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-and-takeda-seek-fda-approval-for-antidepressant-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-and-takeda-seek-fda-approval-for-antidepressant-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/carrots-show-potential-in-diabetes-treatment-through-gut-microbiome-alteration 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carrots-show-potential-in-diabetes-treatment-through-gut-microbiome-alteration 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tune-therapeutics-receives-approval-to-initiate-clinical 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tune-therapeutics-receives-approval-to-initiate-clinical 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-announces-two-key-investigational-oncology 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-announces-two-key-investigational-oncology 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthroughs-and-challenges-in-gene-therapy-a-2024-overview 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthroughs-and-challenges-in-gene-therapy-a-2024-overview 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vergent-bioscience-receives-fda-fast-track-designation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vergent-bioscience-receives-fda-fast-track-designation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-says-lung-cancer-combo-improves-survival-more-than-standard-of-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-says-lung-cancer-combo-improves-survival-more-than-standard-of-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bicycle-therapeutics-partners-with-cancer-research-uk-for-cancer-treatment-development 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bicycle-therapeutics-partners-with-cancer-research-uk-for-cancer-treatment-development 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pila-pharma-ab-announces-preclinical-preclinical-proof-of-concept 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pila-pharma-ab-announces-preclinical-preclinical-proof-of-concept 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/baxter-alzheimers-drug-fails-to-meet-phase-3-endpoints 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baxter-alzheimers-drug-fails-to-meet-phase-3-endpoints 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/applied-tx-craters-as-fda-rejects-lead-product-candidate 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-tx-craters-as-fda-rejects-lead-product-candidate 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-gives-pfizer-s-group-b-strep-vaccine-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-gives-pfizer-s-group-b-strep-vaccine-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-co-ltd-advances-in-narcolepsy-and-alzheimer-s-disease-treatments 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-co-ltd-advances-in-narcolepsy-and-alzheimer-s-disease-treatments 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-inc-maia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-inc-maia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/akero-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akero-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/luspatercept-lenalidomide-combo-demonstrates-safety 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luspatercept-lenalidomide-combo-demonstrates-safety 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-roundup-january-7-2025 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-roundup-january-7-2025 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/concept-medical-announces-successful-sirona-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concept-medical-announces-successful-sirona-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-btk-degrader-nx-5948-yields-high-response 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-btk-degrader-nx-5948-yields-high-response 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-ucb-s-psoriasis-therapy-bimekizumab 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-ucb-s-psoriasis-therapy-bimekizumab 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/simpson-interventions-announces-both-ide-approval-from 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simpson-interventions-announces-both-ide-approval-from 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alleviant-medical-wins-fda-ide-breakthrough-nods-for-no-implant-heart-failure-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alleviant-medical-wins-fda-ide-breakthrough-nods-for-no-implant-heart-failure-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-turns-down-satsumas-nasal-migraine-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-turns-down-satsumas-nasal-migraine-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/accurkardia-receives-fda-breakthrough-device-designation-for-ai-powered-hyperkalemia-detection-solution-using-lead-i-ecg-data 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accurkardia-receives-fda-breakthrough-device-designation-for-ai-powered-hyperkalemia-detection-solution-using-lead-i-ecg-data 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-and-lilly-post-new-data-backing-covid-antibody-cocktails 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-and-lilly-post-new-data-backing-covid-antibody-cocktails 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-fda-granted-priority-review-to-dizal-s-sunvozertinib-new-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-fda-granted-priority-review-to-dizal-s-sunvozertinib-new-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/raphael-pharmaceutical-announces-positive-proof-of 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raphael-pharmaceutical-announces-positive-proof-of 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/restem-receives-fda-fast-track-designation-for-restem-l-for-idiopathic-inflammatory-myopathy 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/restem-receives-fda-fast-track-designation-for-restem-l-for-idiopathic-inflammatory-myopathy 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/opko-health-s-modex-therapeutics-announces-epstein 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opko-health-s-modex-therapeutics-announces-epstein 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reveals-diversity-action-plan-guide-for-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reveals-diversity-action-plan-guide-for-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/metseras-touts-powerful-weight-loss-results-again 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metseras-touts-powerful-weight-loss-results-again 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-announces-strategic-partnership 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verismo-therapeutics-announces-strategic-partnership 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-parp-drug-zejula-approved-in-wider-ovarian-cancer-population 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-parp-drug-zejula-approved-in-wider-ovarian-cancer-population 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-anti-aging-company-just-released-disappointing 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-s-anti-aging-company-just-released-disappointing 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-of-astellas-zolbetuximab-bla 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-of-astellas-zolbetuximab-bla 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alkeus-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/january-2025-1stoncologytm-cancer-intelligence-service 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/january-2025-1stoncologytm-cancer-intelligence-service 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-leash-from-verzenio-in-early-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-removes-leash-from-verzenio-in-early-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/h-c-wainwright-cuts-acelyrin-stock-target-keeps-neutral 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/h-c-wainwright-cuts-acelyrin-stock-target-keeps-neutral 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-protocol-deviations-a-new-fda-draft-guidance-to-ring-in-the-new-year 2025-01-06T22:53:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-protocol-deviations-a-new-fda-draft-guidance-to-ring-in-the-new-year 2025-01-06T22:53:32+00:00 hourly 0.9 https://trial.medpath.com/news/poly-adp-ribose-polymerase-parp-inhibitor-regimens-for-platinum-sensitive-ovarian-frontiers 2025-01-06T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poly-adp-ribose-polymerase-parp-inhibitor-regimens-for-platinum-sensitive-ovarian-frontiers 2025-01-06T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/with-phase-iii-success-pharmaessentia-to-seek-besremi-label-expansion 2025-01-06T22:28:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/with-phase-iii-success-pharmaessentia-to-seek-besremi-label-expansion 2025-01-06T22:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/accelerated-approval-us-fda-explains-when-a-confirmatory-trial-is-underway 2025-01-06T22:19:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accelerated-approval-us-fda-explains-when-a-confirmatory-trial-is-underway 2025-01-06T22:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-therapeutics-announces-2025-strategic-pipeline-priorities-and-provides-corporate-update 2025-01-06T22:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-therapeutics-announces-2025-strategic-pipeline-priorities-and-provides-corporate-update 2025-01-06T22:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/denali-therapeutics-als-drug-trial-falls-short-as-dnl343-misses-primary-endpoint 2025-01-06T21:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denali-therapeutics-als-drug-trial-falls-short-as-dnl343-misses-primary-endpoint 2025-01-06T21:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/updated-acelyrin-s-stock-drops-due-to-mixed-phase-2-data 2025-01-06T21:30:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updated-acelyrin-s-stock-drops-due-to-mixed-phase-2-data 2025-01-06T21:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/stimulating-fat-cells-with-gip-receptor-has-potential-to-treat-obesity 2025-01-06T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stimulating-fat-cells-with-gip-receptor-has-potential-to-treat-obesity 2025-01-06T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/upamostat-combo-demonstrates-tolerability-in-metastatic-pancreatic-cancer 2025-01-06T21:27:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upamostat-combo-demonstrates-tolerability-in-metastatic-pancreatic-cancer 2025-01-06T21:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-announces-initiation-of-dosing-in-phase-2-multiple-ascending-morningstar 2025-01-06T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcturus-therapeutics-announces-initiation-of-dosing-in-phase-2-multiple-ascending-morningstar 2025-01-06T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/mrd-status-prior-to-allo-hsct-shows-strong-prognostic-value-in-aml-mds 2025-01-06T21:09:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrd-status-prior-to-allo-hsct-shows-strong-prognostic-value-in-aml-mds 2025-01-06T21:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-harmony-tpvr-system-gains-ce-mark-approval-cardiovascular-business 2025-01-06T20:23:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-harmony-tpvr-system-gains-ce-mark-approval-cardiovascular-business 2025-01-06T20:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/sti-prevention-method-shows-promise-in-curbing-infections-in-groups-at-high-risk 2025-01-06T20:14:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sti-prevention-method-shows-promise-in-curbing-infections-in-groups-at-high-risk 2025-01-06T20:14:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-star-therapeutics-vga039-for-von-willebrand-disease 2025-01-06T19:51:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-star-therapeutics-vga039-for-von-willebrand-disease 2025-01-06T19:51:09+00:00 hourly 0.9 https://trial.medpath.com/news/second-line-axi-cel-is-efficacious-safe-in-real-world-patients-with-r-r-lbcl-onclive 2025-01-06T19:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/second-line-axi-cel-is-efficacious-safe-in-real-world-patients-with-r-r-lbcl-onclive 2025-01-06T19:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/study-confirms-ct-p42-therapeutic-equivalence-to-reference-aflibercept-in-dme 2025-01-06T19:16:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-confirms-ct-p42-therapeutic-equivalence-to-reference-aflibercept-in-dme 2025-01-06T19:16:19+00:00 hourly 0.9 https://trial.medpath.com/news/dr-levee-on-immune-related-aes-associated-with-icis-in-early-breast-cancer-onclive 2025-01-06T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-levee-on-immune-related-aes-associated-with-icis-in-early-breast-cancer-onclive 2025-01-06T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaessentia-announces-positive-topline-phase-3-data-from-surpass-et-study-biospace 2025-01-06T19:04:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaessentia-announces-positive-topline-phase-3-data-from-surpass-et-study-biospace 2025-01-06T19:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-on-including-tissue-biopsies-in-clinical-trials-biospace 2025-01-06T19:04:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-on-including-tissue-biopsies-in-clinical-trials-biospace 2025-01-06T19:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/cms-issues-permanent-reimbursement-code-for-anktiva-urology-times 2025-01-06T19:00:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-issues-permanent-reimbursement-code-for-anktiva-urology-times 2025-01-06T19:00:31+00:00 hourly 0.9 https://trial.medpath.com/news/viking-therapeutics-and-structure-therapeutics-seen-as-key-partners-in-weight-loss-market 2025-01-06T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viking-therapeutics-and-structure-therapeutics-seen-as-key-partners-in-weight-loss-market 2025-01-06T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-india-gets-cdsco-panel-nod-to-conduct-phase-iii-ct-of-ursodeoxycholic-acid-tablet 2025-01-06T18:49:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-india-gets-cdsco-panel-nod-to-conduct-phase-iii-ct-of-ursodeoxycholic-acid-tablet 2025-01-06T18:49:47+00:00 hourly 0.9 https://trial.medpath.com/news/relativity-047-extended-analysis-of-overall-survival-with-nivolumab-relatlimab-vs 2025-01-06T18:10:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relativity-047-extended-analysis-of-overall-survival-with-nivolumab-relatlimab-vs 2025-01-06T18:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/impact-of-non-abl1-mutations-on-outcomes-in-chronic-myeloid-leukemia 2025-01-06T18:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-of-non-abl1-mutations-on-outcomes-in-chronic-myeloid-leukemia 2025-01-06T18:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/dose-escalation-completed-for-rise-therapeutics-r-3750-and-r-2487-clinical-trials 2025-01-06T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dose-escalation-completed-for-rise-therapeutics-r-3750-and-r-2487-clinical-trials 2025-01-06T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/dog-aging-project-receives-7-million-nih-grant-to-expand-clinical-trial-of-anti-aging-drug 2025-01-06T17:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dog-aging-project-receives-7-million-nih-grant-to-expand-clinical-trial-of-anti-aging-drug 2025-01-06T17:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-s-treatment-for-epidermolysis-bullosa-awarded-fda-orphan-designation 2025-01-06T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-s-treatment-for-epidermolysis-bullosa-awarded-fda-orphan-designation 2025-01-06T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-repairs-limb-girdle-muscular-dystrophy-2b-mutation-and-phenotypes-in-patient 2025-01-06T16:44:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-repairs-limb-girdle-muscular-dystrophy-2b-mutation-and-phenotypes-in-patient 2025-01-06T16:44:10+00:00 hourly 0.9 https://trial.medpath.com/news/insight-003-trial-of-eftilagimod-alpha-combo-in-nsclc-completes-enrollment 2025-01-06T16:38:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insight-003-trial-of-eftilagimod-alpha-combo-in-nsclc-completes-enrollment 2025-01-06T16:38:35+00:00 hourly 0.9 https://trial.medpath.com/news/tarlatamab-earns-uk-approval-for-previously-treated-es-sclc-onclive 2025-01-06T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tarlatamab-earns-uk-approval-for-previously-treated-es-sclc-onclive 2025-01-06T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/news/nanovibronix-completes-pilot-phase-of-us-trial-with-uroshield 2025-01-06T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanovibronix-completes-pilot-phase-of-us-trial-with-uroshield 2025-01-06T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-chemotherapy-antidote-could-improve-recovery-after-mass-general-brigham 2025-01-06T16:13:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-chemotherapy-antidote-could-improve-recovery-after-mass-general-brigham 2025-01-06T16:13:25+00:00 hourly 0.9 https://trial.medpath.com/news/castle-biosciences-gains-new-york-state-approval-for-barrett-s-oesophagus-test 2025-01-06T16:11:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/castle-biosciences-gains-new-york-state-approval-for-barrett-s-oesophagus-test 2025-01-06T16:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/sean-m-healey-amg-center-announces-update-in-als-platform-trial-with-fosigotifator 2025-01-06T16:00:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sean-m-healey-amg-center-announces-update-in-als-platform-trial-with-fosigotifator 2025-01-06T16:00:47+00:00 hourly 0.9 https://trial.medpath.com/news/veliparib-and-temozolomide-combo-does-not-significantly-extend-survival-for-patients-with-glioma 2025-01-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veliparib-and-temozolomide-combo-does-not-significantly-extend-survival-for-patients-with-glioma 2025-01-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/10-clinical-trials-of-2024-hits-misses-and-some-in-between-citeline-news-insights 2025-01-06T15:42:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/10-clinical-trials-of-2024-hits-misses-and-some-in-between-citeline-news-insights 2025-01-06T15:42:34+00:00 hourly 0.9 https://trial.medpath.com/news/adverse-events-of-hepatic-anti-fibrotic-agents-in-phase-3-and-above-clinical-trials-frontiers 2025-01-06T15:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adverse-events-of-hepatic-anti-fibrotic-agents-in-phase-3-and-above-clinical-trials-frontiers 2025-01-06T15:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/serina-therapeutics-advances-parkinson-s-treatment-with-ser-252-clinical-trials-set-for-2025 2025-01-06T15:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serina-therapeutics-advances-parkinson-s-treatment-with-ser-252-clinical-trials-set-for-2025 2025-01-06T15:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/woman-cancer-free-after-uk-s-first-liver-transplant-for-advanced-bowel-cancer 2025-01-06T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/woman-cancer-free-after-uk-s-first-liver-transplant-for-advanced-bowel-cancer 2025-01-06T15:22:00+00:00 hourly 0.9